Fig. 5From: Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinomaCT-scans from a patient with CNS and liver metastases 4Â months after start of INTUVAX treatment but before additional treatment with sunitinib (a and c, respectively) and 6Â months (b) or 12Â months (d) after start of sunitinib treatmentBack to article page